101 related articles for article (PubMed ID: 16278044)
21. Effect of cyclic GMP-increasing agents nitric oxide and C-type natriuretic peptide on bovine chromaffin cell function: inhibitory role mediated by cyclic GMP-dependent protein kinase.
Rodriguez-Pascual F; Miras-Portugal MT; Torres M
Mol Pharmacol; 1996 Jun; 49(6):1058-70. PubMed ID: 8649344
[TBL] [Abstract][Full Text] [Related]
22. Characterization of atrial natriuretic peptide receptors in brain microvessel endothelial cells.
Whitson PA; Huls MH; Sams CF
J Cell Physiol; 1991 Jan; 146(1):43-51. PubMed ID: 1846636
[TBL] [Abstract][Full Text] [Related]
23. Effects of atrial and brain natriuretic peptides upon cyclic GMP levels, potassium transport, and receptor binding in rat astrocytes.
Beaumont K; Tan PK
J Neurosci Res; 1990 Feb; 25(2):256-62. PubMed ID: 2157033
[TBL] [Abstract][Full Text] [Related]
24. Hyperammonemia inhibits the natriuretic peptide receptor 2 (NPR-2)-mediated cyclic GMP synthesis in the astrocytic compartment of rat cerebral cortex slices.
Zielińska M; Fresko I; Konopacka A; Felipo V; Albrecht J
Neurotoxicology; 2007 Nov; 28(6):1260-3. PubMed ID: 17629948
[TBL] [Abstract][Full Text] [Related]
25. CNP, but not ANP or BNP, relax human isolated subcutaneous resistance arteries by an action involving cyclic GMP and BKCa channels.
Garcha RS; Hughes AD
J Renin Angiotensin Aldosterone Syst; 2006 Jun; 7(2):87-91. PubMed ID: 17083062
[TBL] [Abstract][Full Text] [Related]
26. C-type natriuretic peptide applied to the brain enhances exocrine pancreatic secretion through a vagal pathway.
Sabbatini ME; Rodríguez MR; Corbo NS; Vatta MS; Bianciotti LG
Eur J Pharmacol; 2005 Nov; 524(1-3):67-74. PubMed ID: 16263110
[TBL] [Abstract][Full Text] [Related]
27. Natriuretic peptide system in the human retina.
Rollín R; Mediero A; Roldán-Pallarés M; Fernández-Cruz A; Fernández-Durango R
Mol Vis; 2004 Jan; 10():15-22. PubMed ID: 14737067
[TBL] [Abstract][Full Text] [Related]
28. Natriuretic peptide system in the rat lacrimal gland.
Cho ES; Kim SZ; Kim SH; Park BK; Cho KW
Exp Eye Res; 2000 Oct; 71(4):333-40. PubMed ID: 10995554
[TBL] [Abstract][Full Text] [Related]
29. Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism.
Borgeson DD; Stevens TL; Heublein DM; Matsuda Y; Burnett JC
Clin Sci (Lond); 1998 Aug; 95(2):195-202. PubMed ID: 9680502
[TBL] [Abstract][Full Text] [Related]
30. Natriuretic peptides differentially attenuate thrombin-induced barrier dysfunction in pulmonary microvascular endothelial cells.
Klinger JR; Warburton R; Carino GP; Murray J; Murphy C; Napier M; Harrington EO
Exp Cell Res; 2006 Feb; 312(4):401-10. PubMed ID: 16360149
[TBL] [Abstract][Full Text] [Related]
31. Atrial natriuretic peptides elevate cyclic GMP levels in primary cultures of rat ependymal cells.
Wellard J; Rapp M; Hamprecht B; Verleysdonk S
Neurochem Res; 2003 Feb; 28(2):225-33. PubMed ID: 12608696
[TBL] [Abstract][Full Text] [Related]
32. Chronic nitrates blunt the effects of not only nitric oxide but also natriuretic peptides in cardiac myocytes.
Tan T; Zhang Q; Anyadike C; Scholz PM; Weiss HR
Pharmacol Res; 2007 Jul; 56(1):49-55. PubMed ID: 17482833
[TBL] [Abstract][Full Text] [Related]
33. C-type natriuretic peptide inhibits thrombin- and angiotensin II-stimulated endothelin release via cyclic guanosine 3',5'-monophosphate.
Kohno M; Horio T; Yokokawa K; Kurihara N; Takeda T
Hypertension; 1992 Apr; 19(4):320-5. PubMed ID: 1313393
[TBL] [Abstract][Full Text] [Related]
34. Natriuretic peptides modify Pseudomonas fluorescens cytotoxicity by regulating cyclic nucleotides and modifying LPS structure.
Veron W; Orange N; Feuilloley MG; Lesouhaitier O
BMC Microbiol; 2008 Jul; 8():114. PubMed ID: 18613967
[TBL] [Abstract][Full Text] [Related]
35. Characterization of Relaxant Responses to Natriuretic Peptides in the Human Microcirculation In Vitro and In Vivo.
Edvinsson ML; Ahnstedt H; Edvinsson L; Andersson SE
Microcirculation; 2016 Aug; 23(6):438-46. PubMed ID: 27207741
[TBL] [Abstract][Full Text] [Related]
36. Natriuretic peptides stimulate cyclic guanosine monophosphate production in human saphenous vein and internal mammary artery.
Bonatti J; Dichtl W; Lercher A; Puschendorf B
Eur J Cardiothorac Surg; 2000 Feb; 17(2):175-81. PubMed ID: 10731654
[TBL] [Abstract][Full Text] [Related]
37. HS-142-1, a novel non-peptide ANP antagonist, blocks the cyclic GMP production elicited by natriuretic peptides in PC12 and NG108-15 cells.
Toki S; Morishita Y; Sano T; Matsuda Y
Neurosci Lett; 1992 Jan; 135(1):117-20. PubMed ID: 1311820
[TBL] [Abstract][Full Text] [Related]
38. Natriuretic peptides as therapy in cardiac ischaemia/reperfusion.
Kousholt BS
Dan Med J; 2012 Jun; 59(6):B4469. PubMed ID: 22677252
[TBL] [Abstract][Full Text] [Related]
39. C-type natriuretic peptide protects the retinal pigment epithelium against advanced glycation end product-induced barrier dysfunction.
Dahrouj M; Alsarraf O; Liu Y; Crosson CE; Ablonczy Z
J Pharmacol Exp Ther; 2013 Jan; 344(1):96-102. PubMed ID: 23086231
[TBL] [Abstract][Full Text] [Related]
40. Primary malignant tumors of the heart: four cardiovascular hormones decrease the number and DNA synthesis of human angiosarcoma cells.
Vesely BA; Alli A; Song S; Sanchez-Ramos J; Fitz SR; Gower WR; Vesely DL
Cardiology; 2006; 105(4):226-33. PubMed ID: 16534199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
